1. Fuster V, Rydén L, Cannom D et al. ACC/ AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology/ American Heart Associate task force of practice guidelines and the European Society of Cardiology committee for practice guidelines: developed in collaboration with the European Heart Rhythm Associate then the Heart Rhythm Society. Circulation 2006; 114: 257– 354.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370– 2375.
3. Benjamin EJ, Wolf PA, D’Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946– 952.
4. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825– 1833.
5. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow‑Up Study. Am J Med 1995; 98: 476– 484.
6. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population‑based estimates. Am J Cardiol 1998; 82: 2N– 9N.
7. Allessie M, Ausma J, Schotten U. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230– 246.
8. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complication and potential therapeutic target. Am J Cardiol 2003; 91: 9G– 14G.
9. Miyasaka Y, Barnes M, Gersh B et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980– 2000. Stroke 2005; 36: 2362– 2366.
10. Chapman N, Huxley R, Anderson C et al. Effects of a perindopril‑based blood pressure‑lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke 2004; 35: 116– 121.
11. Kumagai K, Nakashima H, Urata H et al. Effects on angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197– 2204.
12. McEwan PE, Gray GA, Sherry L et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98: 2765– 2773.
13. Makkar K, Sanoski CA, Spinler S. Role of angiotensin‑converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009; 29: 31– 48.
14. Garg S, Narula J, Marelli C et al. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am J Cardiol 2006; 97: 921– 925.
15. Neuberger HR, Schotten U, Verheule Set al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005; 111: 30– 37.
16. Schaer BA, Schneider C, Jick SS et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case‑ control study. Ann Intern Med 2010; 152: 78– 84.
17. Verdecchia P, Reboldi G, Gattobigio R et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218– 223.
18. Heckbert SR, Wiggins KL, Glazer NL et al. Antihypertensive treatment with ACE inhibitors or beta‑blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538– 544.
19. Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin‑converting‑enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611– 616.
20. Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new hypertensive drugs in elderly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension‑ 2 study. Lancet 1999; 354: 1751– 1756.
21. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new‑onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertension 2008; 26: 403– 411.
22. Watchell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new‑onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712– 719.
23. Salehian O, Healey J, Stambler B et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Protection Evaluation (HOPE) study. Am Heart J 2007; 154: 448– 453.
24. Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547– 1559.
25. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-‑standing persistent atrial fibrillation. Eur Heart J 2003; 24: 2090– 2098.
26. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long‑lasting persistent atrial fibrillation. Circulation 2002; 106: 331– 336.
27. Belluzzi F, Sernesi L, Preti P et al. Prevention of recurrent lone atrial fibrillation by the angiotensin‑II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24– 29.
28. Van Noord T, Crijns H, van den Berg M et al. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005; 5: 3.
29. Healey J, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin‑converting enzyme inhibitors and angiotensin receptor blockers: a meta‑analysis. J Am Coll Cardiol 2005; 45: 1832– 1839.